COMMUNIQUÉS West-GlobeNewswire

Ardelyx Presents Real-World Data at ASN Kidney Week 2026 Showing Serum Phosphate Reductions Following XPHOZAH® (tenapanor) Initiation With or Without Phosphate Binders
23/10/2026
Real-world analysis showed serum phosphate reductions following XPHOZAH initiation across all phosphate binder groups evaluated Additional data highlighted the challenges of managing hyperphosphatemia and the morbidity [...]
Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026
23/10/2026
>90% free APRIL suppression sustained through 12 weeks, supporting Q12W dosing interval ~70% reduction in Gd-IgA1 at 12 weeks ~33-day half-life NAVIGATE-2 Phase 2 trial enrolling, with initial data expected in the [...]
The Ensign Group Schedules Third Quarter 2026 Earnings Call for Wednesday, October 28, 2026
23/10/2026
SAN JUAN CAPISTRANO, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign ™ group of companies, which invest in and provide skilled nursing and senior living [...]
J-Star Holding Co., Ltd. Files Interim Financial Report on Form 6-K
23/10/2026
Company is Highlighting Strategic Focus on U.S. Opportunities, Balance Sheet Improvement, and Management Commitment TAICHUNG, Taiwan and HOUSTON, Oct. 23, 2026 (GLOBE NEWSWIRE) -- J-Star Holding Co., Ltd. (Nasdaq: YMAT [...]
Le KFSH réduit le délai d’attente pour un rendez-vous d’échocardiographie de 126 jours à un seul
23/10/2026
RIYAD, Arabie saoudite, 23 oct. 2026 (GLOBE NEWSWIRE) -- Le King Faisal Specialist Hospital and Research Centre (KFSH) a réduit le délai d’attente pour le premier rendez-vous d’échocardiographie disponible dans son [...]
Novartis remibrutinib delivered comprehensive disease control in Phase III RMS trials, with proven, robust safety profile
23/10/2026
Remibrutinib achieved significant and clinically meaningful reduction in relapses vs. teriflunomide, to approximately 1 relapse every 13 years, without the need for chronic B-cell depletion¹˒ ² MRI disease activity [...]
Idorsia presents outstanding results with daridorexant in children and adolescents with insomnia and an expanding body of evidence in adults at Sleep Europe 2026
23/10/2026
Daridorexant, a dual orexin receptor antagonist, is the first investigational treatment in its class to demonstrate positive results in pediatric insomnia disorder, an area in which significant unmet needs remain for [...]
Genmab Announces Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer
23/10/2026
Company Announcement COPENHAGEN, Denmark; October 23, 2026 Phase 3 RAINFOL™-02 trial met its primary endpoint of progression-free survival (PFS) and its key secondary endpoint of overall survival (OS) with rinatabart [...]
Collaboration entre Fortrea et Omico pour faire progresser le développement de médicaments oncologiques basés sur des biomarqueurs
23/10/2026
Cette collaboration vise à améliorer la planification des essais cliniques et à élargir l’accès des patients aux études ciblées par biomarqueurs en Australie Points clés Cette collaboration vise à accélérer la recherche [...]
NeOnc Breaks Through Key Levels, as Brain-Cancer Stock’s Catalysts Continue
23/10/2026
Price barriers are falling, as improving technicals meet a string of clinical, international, and regulatory milestones with November 17’s FDA meeting next on the calendar. DENVER, Oct. 23, 2026 (GLOBE NEWSWIRE) -- ( [...]
Roche presents interim phase III data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)
23/10/2026
Sefaxersen achieved a statistically significant 43.1% reduction in proteinuria, a key indicator of kidney damage, relative to placebo at 37 weeks with consistent treatment effects across all prespecified patient [...]
Le CHMP recommande l’approbation de TALVEY®▼ (talquetamab) de Johnson & Johnson, en association avec le daratumumab, dans une ligne de traitement plus précoce du myélome multiple en rechute/réfractaire
23/10/2026
Sous réserve de son approbation, l’association TALVEY ® et daratumumab constituerait la seule association thérapeutique comprenant un anticorps bispécifique ciblant le GPRC5D dans le traitement du myélome multiple en [...]
Immutep Announces Presentation of Quality of Life Data from EFTISARC-NEO Phase II Trial at ESMO 2026
23/10/2026
Quality of life remained stable during neoadjuvant treatment with efti, pembrolizumab and radiotherapy, with statistically significant improvement after surgery SYDNEY, AUSTRALIA, Oct. 23, 2026 (GLOBE NEWSWIRE) -- [...]
Humacyte at ASN Kidney Week: Phase 3 Trial Built for Women Shows ATEV Advantage Over Fistula, Getting Patients Off Catheters Months Sooner
23/10/2026
- The presenter, Dr. Roy-Chaudhury said, “These results give the nephrology community a strong reason to rethink our approach to access decisions for women and, once approved by the FDA, to consider the ATEV as a [...]
ImPact Biotech Reports Encouraging Early Clinical Results From Phase 1 Study of Padeliporfin VTP in Pancreatic Cancer, with Seven Previously Unresectable Patients Undergoing Surgical Resection Following Treatment
23/10/2026
Completion of light dose-escalation Part A of Phase 1 study identifies regimen for further evaluation in Part B, supporting advancement of Padeliporfin VTP for treatment of locally advanced pancreatic cancer 75% (9/12) [...]
Lexicon Pharmaceuticals Provides Update on Baseline Patient Characteristics for Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Hypertrophic Cardiomyopathy
23/10/2026
-- Patient demographics consistent with prior studies of other agents in HCM and reflect real-world clinical practice -- -- Mean baseline KCCQ-CSS of 59 shows considerable symptom burden at study entry – -- Substantial [...]
IRADIMED CORPORATION to Hold Third Quarter 2026 Financial Results Conference Call on October 30, 2026
23/10/2026
ORLANDO, Fla., Oct. 23, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2026 third quarter financial results before the market opens on Friday, October 30, [...]
Onconetix Provides Additional Strategic Bridge Financing to Realbotix LLC in Continued Support of Pending Acquisition
23/10/2026
Additional $500,000 Advance to Support Growth Initiatives and Working Capital of Realbotix LLC Total Drawn Under Facility Now $3,000,000; Non-Interest Bearing Facility Automatically Cancelled and Discharged in Full Upon [...]
Microbot Medical® Attending Key Medical Conference to Engage with Decision-makers as it Continues to Expand Presence Across the U.S.
23/10/2026
Opportunity to Connect with Hospital Administrators and Physicians to Foster Expanded Adoption of the LIBERTY System HINGHAM, Mass., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and [...]

Pages